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T
ype 2 diabetes is a chronic disease
characterized by coexisting insulin
deﬁciency and insulin resistance,
with the resultant hyperglycemia leading
to micro- and macrovascular complica-
tions. A large number of intervention tri-
als demonstrated that improving
glycemic control achieves considerable
reductions of such complications (1–7).
It has been estimated using the ho-
meostasis multiple assessment (HOMA)
that, at the time of diagnosis, 50% of
pancreatic -cell function has been lost,
with almost 4% further loss of function
expected per year thereafter (8,9). There-
fore, type 2 diabetes is a chronic progres-
sive disease characterized by worsening
hyperglycemia and escalating deteriora-
tion in the function of pancreatic -cells
and loss of -cell mass (10). Because of
the progressive nature of the disease, an
evolving treatment strategy is therefore
necessary to maintain both fasting and
postprandial glycemic control. Recently,
an American Diabetes Association (ADA)
andEuropeanAssociationfortheStudyof
Diabetes (EASD) Consensus recom-
mended a target of A1C 7% for good
glucose control in clinical practice (11).
Insulin therapy is required when dietary
restrictions and lifestyle modiﬁcations
combined with oral hypoglycemic agents
(OHAs) failed to provide acceptable met-
abolic control (12). One major lesson
learned from the milestone U.K. Prospec-
tive Diabetes Study (UKPDS) is the in-
creasing requirement for multiple
therapies in patients with type 2 diabetes
to achieve blood glucose (BG) target con-
trol (13).
TheaugmentationofinsulintoOHAs
contributed to several beneﬁcial meta-
bolic effects, as recently reviewed (14).
However, there is ongoing debate as to
whether it is more rewarding to target
postprandial BG concentrations with
meal-related insulin, or to target fasting
BG concentrations with basal insulin.
Monnier et al. (15,16) provided data to
explaintherelativecontributionoffasting
and postprandial BG to A1C in patients
with mild-to-moderate hyperglycemia
(A1C 7.3%) than in those with more
poorly controlled blood glucose.
The APOLLO trial (AP arallel design
comparing an Oral antidiabetic drug
combination therapy with either Lantus
once daily or Lispro at mealtime in type 2
diabetic patients failing Oral treatment), a
multicenter randomized prospective
study, addressed the issue of targeting ei-
therprandialorfastingBGconcentrations
(17).
HOW TO INITIATE BASAL
OR PRANDIAL INSULIN
THERAPY: THE APOLLO
TRIAL— In the 44-week parallel open
studythatwasperformedin69studysites
across Europe and Australia, 418 individ-
uals with type 2 diabetes inadequately
controlled by OHAs (excluding -gluco-
sidase inhibitors) were randomly as-
signed to either basal insulin glargine
(Lantus; sanoﬁ-aventis, Frankfurt, Ger-
many) once daily, at the same time every
day, or to mealtime insulin lispro (Huma-
log; Eli Lilly, Bad Homburg, Germany)
administered thrice daily in addition to
the OHAs. The primary objective was to
comparethechangeinA1Cfrombaseline
to end point (week 44) between the two
regimens. In addition, secondary objec-
tives included the percentage of partici-
pantswhoachievedA1Cof6.5or7.0%or
less, respectively, the number of hypogly-
cemic events, the change in body weight
in both treatment arms, and treatment
satisfaction.
Maleandfemalepatientswereeligible
for enrollment if they were aged between
18 and 75 years. Additional inclusion cri-
teria: type 2 diabetes for 1 year with an
A1C concentration between 7.5 and
10.5%, OHA treatment for at least 6
months with stable doses for 3 months
before study entry, fasting BG concentra-
tions of 6.5 mmol/l, and BMI of 35
kg/m
2. All participants were willing to
perform self-monitoring of BG, and all
provided written informed consent for
their participation before study entry.
Of 412 patients in the intention-to-
treat population, a total of 35 patients
were excluded because of major protocol
deviations during the study. Thus, the
per-protocol population comprised 377
patients (186 in the insulin glargine and
191 in the insulin lispro groups) who
were included in our analyses. After ran-
domization, most patients received met-
formin therapy throughout the study
(156[76%]and153[74%])intheinsulin
glargine and insulin lispro treatment
groups, respectively). Most patients in
both groups were prescribed glimepiride,
with only 11 (6%) patients assigned to
insulin glargine, and 14 (7%) to insulin
lispro, without glimepiride. Patient de-
mographics(meanage,59.7yearsinboth
arms; BMI: 29.2/29.3 kg/m
2; duration of
OHA treatment: 6.8/6.3 years, glycemic
control: A1C: 8.73/8.67%, and fasting
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spectively) were similar at baseline.
During the treatment phase, insulin
doses were adjusted by a forced titration
regimen to a target fasting BG 5.5
mmol/l in the insulin glargine group, and
a preprandial BG 5.5 mmol/l and a
postprandial BG 7.5 mmol/l in the in-
sulinlisprogroup,inaccordancewiththe
insulin titration algorithms proposed by
the European Diabetes Policy Group in
1999 (18). Insulin dose titration algo-
rithms and monitoring are presented in
Tables1and2.Atthestartofscreening,at
week 20, and at week 44 (study end
point), a validated diabetes treatment sat-
isfaction questionnaire was distributed
among the patients (19).
Hypoglycemia was deﬁned as an
event with or without symptoms consis-
tentwithhypoglycemia,notrequiringthe
assistance of another person, and associ-
ated with BG concentration of 3.3
mmol/l. Severe hypoglycemia was de-
ﬁned as an event with symptoms consis-
tent with hypoglycemia, necessitating
assistance, associated with a BG concen-
tration of 2.0 mmol/l, or recovery after
oral carbohydrate, intravenous glucose,
or glucagon administration. Nocturnal
hypoglycemia was deﬁned as hypoglyce-
mia, occurring while the individual was
asleep and before arising in the morning.
Whenever participants awoke during the
night and experienced symptoms of hy-
poglycemia, self-monitoring of BG was
performed and documented in the pa-
tients’ diary.
Bothtreatmentregimenswereequally
effective in lowering A1C concentrations
totarget(7%)atstudyend,withsimilar
differences between the adjusted means
(1.71 vs. 1.87%), which was within
the predeﬁned 0.4% limit for parity for
the differences of A1C between the
groups (Fig. 1).
Figure 2 illustrates reductions of fast-
ing BG concentrations over the 44-week
trial period as well as the difference in the
degree of change from baseline to end
point between the groups (P  0.0001).
Insulin glargine achieved a reduction in
the fasting glucose level from 10.4 to 6.2
mmol/l (Fig. 2). In comparison, a much
smaller reduction in fasting glucose level
from 9.8 to 8.08 mmol/l was seen in the
insulin lispro group (Fig. 2).
Compared with baseline, 106 (57%)
patients in the insulin glargine group and
131 (69%) patients in the insulin lispro
group achieved the A1C target of 7%
(Table 3). Signiﬁcantly more patients in
the insulin glargine group reached the
fasting BG target of 5.5 mmol/l than
with insulin lispro at study end point (71
[38%]) versus 11 [6%]) (Table 3). Con-
versely, a signiﬁcantly greater reduction
of the 2-h postprandial BG was achieved
with insulin lispro than insulin glargine
after breakfast: 4.6 vs. 4.2 mmol/l (P 
0.0421); lunch: 4.3 vs. 3.1 mmol/l
(P  0.0001); and dinner: 5.0 vs. 3.2
mmol/l (P  0.0001), respectively. Both
insulin preparations were also effective
beyond the targets of their titration algo-
rithms. Insulin glargine resulted in a
highly signiﬁcant (P  0.0001) absolute
reduction of mean daytime glucose level
from baseline to end point: 9.9  2.0 to
6.9  1.5 mmol/l, which corresponds to
3.0  2.1 mmol/l. The insulin lispro
groupshowedanabsolutereductionfrom
baseline to end point of 9.7  2.9 to
7.1  1.8 mmol/l corresponding to
1.8  2.3 mmol/l, which was also
highly signiﬁcant (P  0.0001).
Themeanscorefortreatmentsatisfac-
tion improved in both groups from base-
line to end point, but the magnitude of
change was signiﬁcantly greater with in-
sulin glargine than with insulin lispro
Table 1—Insulin glargine dose titration algorithm and monitoring
Starting dose: 10 IU/day
Titration monitoring Direct investigator contact. Fasting BG and
insulin dose submitted to coordinating
center by electronic data capture.
Additional weekly calls to adjust insulin
dose if A1C 7%
Insulin dose titration
algorithm If self-monitored fasting BG for 2 consecutive
days with no severe hypoglycemia:
8.9 mmol/l (160 mg/dl) Add 8 IU/day
7.8 to 8.9 mmol/l (140 to 160 mg/dl) Add 6 IU/day
6.7 to 7.8 mmol/l (120 to 140 mg/dl) Add 4 IU/day
5.5 to 6.7 mmol/l (100 to 120 mg/dl) Add 2 IU/day
5.5 mmol/l (100 mg/dl) No further
titration
Table 2—Insulin lispro dose titration algorithm and monitoring
Starting dose:
4 IU/meal
Titration
monitoring Direct investigator contact. Fasting BG and
insulin dose submitted to coordinating center
by electronic data capture. Additional weekly
calls to adjust insulin dose if A1C 7%
Preprandial BG
Insulin dose
titration
algorithm 10.3 mmol/l (185 mg/dl) Add 3 IU before main
meal
8.3 to 11.1 mmol/l (150 to 200 mg/dl) Add 2 IU before main
meal
5.5 to 8.3 mmol/l (100 to 150 mg/dl) No further titration
Postprandial BG
Insulin dose
titration
algorithm 10.3 mmol/l (185 mg/dl) Add 2 IU before main
meal
7.5 to 10.3 mmol/l (135 to 185 mg/dl) Add 1 IU before main
meal
7.5 mmol/l (135 mg/dl) No further titration
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3.49; P  0.0001) (Fig. 3).
As can be seen in Fig. 4, the rates of
all, including conﬁrmed all (BG 3.3
mmol/l), symptomatic, and conﬁrmed
symptomatic hypoglycemic episodes (BG
3.3 mmol/l), were signiﬁcantly lower
withinsulinglarginethanwithinsulinlis-
pro (all P  0.0001). However, the rates
of nocturnal, conﬁrmed nocturnal, and
severe hypoglycemic episodes were com-
parable in both groups (Fig. 4).
Weight gain was recorded between
baselineandendpointinboththeinsulin
glargine (3.01  4.33 kg) and insulin lis-
pro (3.54  4.48 kg) groups, although
the difference did not reach signiﬁcance
(P  0.23). There was no signiﬁcant vari-
ation in the rates of adverse and severe
adverseeventsbetweenthetwotreatment
groups.
Asimilarstudy,theTreatingtoTarget
in Type 2 Diabetes Trial (4-T study), re-
cently published the 1-year interim anal-
ysis (20). In their basal insulin treatment
group, insulin detemir (Novo Nordisk,
Bagsvaerd, Denmark) was used once or
twice daily and insulin aspart (Novo Nor-
disk) administered premeal thrice daily,
representing the prandial insulin treat-
ment group. Data on an additional group
ofpatientswhoreceivedpremixedinsulin
twice daily is not discussed here. Exclud-
ingthelatter,thestudydesignandoverall
baseline characteristics were analogous to
those in the APOLLO trial.
The reduction of A1C in both (basal
andprandial)treatmentgroupswaslower
in the 4-T study than in the APOLLO trial
(Table 3). Furthermore, twice as many
patients in the basal insulin cohort
achievedtargetA1C7%intheAPOLLO
trialcomparedwiththe4-Tstudy,despite
apparently equivalent insulin doses ad-
ministered in both studies, and despite
the twice-daily dose of basal insulin det-
emir that was required in 34% of the pa-
tients in the 4-T study (Table 3). In the
APOLLO trial, the quality-of-life assess-
ment improved in both groups with sig-
niﬁcant (P  0.0001) advantage of basal
insulin treatment over the prandial regi-
men, using a different quality-of-life as-
sessment score (21). In the 4-T study,
there was no signiﬁcant difference be-
tween the groups (Table 3).
Both studies also noted a signiﬁcantly
lower risk of hypoglycemia with basal
comparedwithprandialinsulintreatment
(Table3).Thepatientsofthe4-Tstudyon
insulin detemir reported on 50% less in-
cidencesofhypoglycemiaperpatientyear
compared with those on insulin glargine
in the APOLLO trial. This effect may be
explained by the lower magnitude of A1C
reduction in the 4-T study group com-
pared with baseline (	 baseline versus
endpoint1.75intheAPOLLOtrialand
0.80inthe4-Tstudy).Weightgainafter
1 year was signiﬁcantly lower in the basal
insulin detemir group compared with the
prandial insulin aspart group in the 4-T
study,whereasweightgainafter44weeks
was only slightly less in the basal insulin
glargine group, but the difference with
prandial insulin lispro did not reach sta-
tistical signiﬁcance in the APOLLO trial.
SHOULD NPH INSULIN OR
INSULIN GLARGINE BE
USED FOR BASAL INSULIN
THERAPY?— It has been shown that
the supplementation of basal insulin re-
duces the entire 24-h fasting BG proﬁle
(22). This improvement results predomi-
nantly from suppression of overnight he-
patic glucose production, both via direct
effects on the liver and indirect effects
Figure 1—Improvement in A1C with insulin glargine plus OHAs (f) versus insulin lispro plus
OHAs ( ) from baseline to end point (44 weeks) in the per-protocol population. Change from
baseline not signiﬁcantly different between both groups.
Figure 2—Reduction in fasting blood glucose (FBG) with insulin glargine plus OHAs versus
insulin lispro plus OHAs from baseline to end point (44 weeks) in the per-protocol population.
Change from baseline signiﬁcantly greater in the glargine group.
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lease from adipose tissue. Furthermore,
targeting fasting BG levels reduce the
overall glucose load and may improve
pancreatic -cell insulin secretion to a
certain extent (23). Therefore, basal insu-
lin as a ﬁrst-line insulin initiation therapy
isnowrecommendedinajointconsensus
guideline by the ADA and EASD (11).
Clinical trials have demonstrated that
type 2 diabetic patients treated with insu-
lin glargine exhibited signiﬁcant im-
provements in glycemic control, which
are at least equivalent (24–27), or supe-
rior (28,29), to improvements associated
with NPH insulin. Furthermore, a recent
meta-analysis concluded that patients
treated with insulin glargine are at lower
risk of hypoglycemia, and in particular,
nocturnal hypoglycemia, compared with
NPHinsulin-treatedpatients(30).Tofur-
ther clarify this issue of the overnight ac-
tion proﬁle of insulin glargine and NPH
insulin, a randomized placebo-controlled
double-blind three-way crossover clamp
study in type 2 diabetic patients, compar-
ing bedtime injections of either insulin
glargine or NPH insulin, was conducted
toinvestigatetheratesofendogenousglu-
cose production and glucose disposal
during the night and in the morning (31).
The study conﬁrmed delayed onset of in-
sulin glargine compared with NPH insu-
lin in these patients (31). Insulin glargine
was associated with a greater reduction of
endogenous glucose production in the
morning between 6:00 and 8:00 A.M.
comparedwithNPHinsulin,whenthein-
sulins were administered at bedtime. The
joint actions of insulin glargine would
therefore be expected to contribute to the
reduced risk of nocturnal hypoglycemia
andlowerfastingBGcomparedwithNPH
insulin (31).
Insulin glargine has an additional ad-
vantage over NPH insulin. It can be ad-
ministered once daily at the same time of
day, owing to its relatively peakless and
extended hypoglycemic proﬁle in type 2
diabetic patients, whereas NPH insulin
requires to be given twice daily in most
cases (24,28,32).
SUMMARY AND
CONCLUSIONS — The APOLLO
trial, designed as a noninferiority study,
clearly demonstrated that a single dose of
basal insulin glargine is as effective as
thrice-dailyprandialinsulinlisproincon-
trollingglucosemetabolismwhenusedin
combination with OHAs in individuals
with type 2 diabetes. Moreover, the basal
insulin regimen was associated with a sig-
niﬁcantly lower risk of hypoglycemia and
a greater improvement in quality of life
and treatment satisfaction compared with
the prandial insulin regimen. Fewer insu-
lin injections and less self-monitoring of
BG required with basal insulin glargine
therapy may have contributed to the
greatertreatmentsatisfactionexperienced
compared with a thrice-daily prandial in-
sulin regimen.
A comparable study, the 4-T study,
using different basal and prandial insulin
analogsanddifferenttitrationalgorithms,
documented a similar beneﬁcial effect of
the basal insulin approach with respect to
hypoglycemic risk and body weight
increase.
Overall, insulin glargine has proved
superior to NPH insulin in basal insulin
regimens for the management of type 2
diabetes. Recent results of a 5-year long-
term study with insulin glargine versus
NPH insulin have also demonstrated no
harmful effects on diabetic retinopathy
progression with insulin glargine over
that expected by BG lowering, a lower in-
cidence of hypoglycemic episodes, and
less weight gain. These data were recently
published (33).
The addition of insulin glargine to
OHAsisasimpleandwell-toleratedinter-
vention that may prove helpful in over-
coming major barriers to timely insulin
initiation in settings of both primary and
secondary care (34). Furthermore, it has
been demonstrated that the use of a sim-
ple self-administered titration algorithm
is equally as effective at improving glyce-
mic control as is titration management by
staff at hospital-based diabetes centers
Figure 3—Change in treatment satisfaction in
bothgroupsasanalyzedbytheDiabetesTreat-
ment Satisfaction Questionnaire (DTSQ [19]).
Change from baseline signiﬁcantly greater in
the glargine group. f, Insulin glargine 

OHAs;  , insulin lispro 
 OHAs.
Table 3—Main outcomes in the APOLLO trial and the 4-T study
APOLLO 4-T
Target A1C 7%
at 44 weeks
Target A1C 7%
at 52 weeks
Basal* Prandial† Basal* Prandial†
A1C (%)
At baseline 8.73 8.67 8.40 8.60
At endpoint 6.98 6.80 7.60 7.20
	 (baseline vs. endpoint) 1.75 1.87 1.40
Responder rate (% patients
achieving A1C target)
7.0% 57 69 28 49
6.5% 30 38 8 24
Responder rate (% patients
achieving FBG target) 38 6
Insulin dose (IU/day) at end
point 42 45 42 56
Treatment satisfaction score‡
(	 change from baseline) 
6.23 
2.74 0 0.02
Number of overall hypoglycemic
events per patient-year 5.2 24.0 (4.6) 2.3 12.0 (5.2)
Change in body weight
(	 kg from baseline) 
3.0 
3.5 
1.9 
5.7
*Basal insulin: insulin glargine for APOLLO trial, insulin detemir for 4-T study. †Prandial insulin: insulin
lispro for APOLLO trial, insulin aspart for 4-T study. ‡Assessed by Diabetes Treatment Satisfaction Ques-
tionnaire scores (19) in the APOLLO trial and assessed by EuroQol 5-Dimension Self-Report Questionnaire
scores (21) in the 4-T study.
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study of daily practice in 10,000 indi-
viduals with type 2 diabetes inadequately
controlled on OHAs conﬁrmed the bene-
ﬁts from supplementation of basal insulin
treatmentwithglargine,sincethepatients
demonstrated improved glycemic control
with little or no weight gain (36).
Finally, when basal insulin therapy in
type 2 diabetes is insufﬁcient to control
daily BG proﬁles, a single injection of
prandial insulin before the mealtime that
induces the largest postprandial BG ex-
cursion(measured2hafterthestartofthe
meal) may be given (37). Over time and
with progression of the disease, addi-
tional prandial boluses of insulin may be
requiredtosustaindaytimeglycemiccon-
trol. This strategy of basal insulin to con-
trol fasting BG ﬁrst and, if needed,
followed by an additional single prandial
insulininjection(“basalplus”concept)of-
fers a simple, stepwise approach in pro-
gressing from a basal insulin to a basal-
bolus regimen (37,38).
In conclusion, evidence from the
APOLLO trial suggests that the addition of
basal insulin analog glargine to therapies
with OHAs can be regarded as a ﬁrst-line
insulin initiation approach in inadequately
controlled type 2 diabetes (39).
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